Results 1 to 10 of about 2,141 (187)
Efficacy and Safety of JAK1 Inhibitor Abrocitinib in Atopic Dermatitis [PDF]
Pharmaceutics, 2023 Abrocitinib is a JAK1 selective inhibitor recently approved for the treatment of moderate-to-severe atopic dermatitis in adults. It has demonstrated efficacy and safety in several clinical trials, both in children and adults, in monotherapy, and compared
Luis Puig +2 more
exaly +5 more sources
Successful treatment of alopecia universalis with abrocitinib: a case report
Journal of Dermatological Treatment, 2023 Abrocitinib, a highly selective inhibitor of Janus kinase 1 (JAK1), has been approved for the treatment of moderate-to-severe atopic dermatitis (AD).
Yagang Zuo
exaly +3 more sources
Cells, 2022 Background and Purpose: Neuroinflammation has been shown to play a critical role in secondary craniocerebral injury, leading to poor outcomes for TBI patients.
Gao Yalong, Wang Cong, Fanglian Chen
exaly +4 more sources
A Report of Eruptive Pruritic Papular Porokeratosis Treated with Abrocitinib
Clinical, Cosmetic and Investigational Dermatology, 2023 Jiali Xia, Guan Jiang Department of Dermatology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221002, People’s Republic of ChinaCorrespondence: Guan Jiang, Department of Dermatology, The Affiliated Hospital of Xuzhou Medical University ...
Guan Jiang
exaly +3 more sources
Efficacy and Safety of Variable-Dose Versus Continuous-Dose Abrocitinib Treatment in Patients with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis [PDF]
Dermatology and TherapyIntroduction Signs and symptoms of atopic dermatitis (AD) can fluctuate over time, necessitating a flexible dosing treatment approach for long-term management.
Jonathan I. Silverberg +5 more
doaj +2 more sources
Abrocitinib Achieves Early and Complete/Near-Complete Skin Clearance Plus Itch-Free State in Atopic Dermatitis: Phase 3 Pooled Post Hoc Analysis [PDF]
Dermatology and TherapyIntroduction Abrocitinib, a Janus kinase inhibitor, is approved for patients with moderate-to-severe atopic dermatitis. Methods This post hoc analysis assessed the onset and depth of response of abrocitinib 100 or 200 mg in achieving the stringent ...
Stephen Weidinger +9 more
doaj +2 more sources
Journal of Dermatological Treatment, 2023 Background Differences in atopic dermatitis (AD) disease course and manifestation with age may extend to treatment response. Objective To evaluate response maintenance with continuous-/reduced-dose abrocitinib or withdrawal and response to treatment ...
Lawrence F Eichenfield +2 more
exaly +2 more sources
A Case of Perioral Dermatitis Successfully Treated with Abrocitinib
Clinical, Cosmetic and Investigational Dermatology, 2023 Perioral dermatitis (POD) is a chronic inflammatory skin disease that primarily affects females between the ages of 16 and 45. Conventional therapies face the challenge of limited efficacy and a high recurrence rate. In this report, we present the case of a 26-year-old male patient with POD who was successfully treated using the Janus kinase (JAK ...
Yang Ding, Yan Teng, Yibin Fan
exaly +4 more sources
Frontiers in ImmunologyIntroductionConventional rosacea treatments are not uniformly pervasive, and the adverse reactions can potentially constrain their utility. The clinical use of JAK1 inhibitors upadacitinib and abrocitinib in the treatment of refractory rosacea has rarely
Xian Jiang
exaly +3 more sources
Abrocitinib and dupilumab bridging therapy for bullous pemphigoid with insufficient response to initial corticosteroid therapy: a case report [PDF]
Frontiers in ImmunologyBullous pemphigoid (BP) is a chronic autoimmune blistering disease predominantly affecting the elderly, with conventional immunosuppressive treatments often limited by insufficient efficacy and severe adverse effects.
Hongchan Zhang +4 more
doaj +2 more sources